Answers are grounded in this paper and cite their sources.
Abstract Objective This article reviews the cellular and rheologic mechanisms of neovascularization (NV) and fibrinolysis in chronic ischemia. These mechanisms provide an explanation for the proteomic and cytometry data obtained from patients with chronic limb-threatening ischemia (CLTI) who were successfully treated with granulocyte colony-stimulating factor (G-CSF). Rationale G-CSF was used in CLTI to promote NV by progenitor cell mobilization. This review was prompted by the significant G-CSF-induced neutrophilia after each G-CSF administration. Neutrophils had been considered antiangiogenic and prothrombotic. However, angiographic evidence of arteriogenesis and fibrinolysis was observed in patients with CLTI treated with a novel G-CSF regimen (filgrastim 7-10 μg/kg every 72 hours for up to 10 doses). Enzyme-linked immunosorbent assays identified significant (P < .01) elevation of the concentration proangiogenic serum proteins and of plasmin (>10-fold) and fibrin degradation products (>5-fold) in plasma. Levels peaked one day after each G-CSF dose, as did the absolute neutrophil count. Levels decreased toward baseline before the next dose, in conjunction with the absolute neutrophil count. No hemorrhage occurred during the month of G-CSF treatment. Methods Multi-disciplinary literature review facilitated by artificial intelligence. Results Evidence has emerged regarding the context-dependent role of neutrophils in modulating both angiogenesis and fibrinolysis. The proangiogenic impact of activated neutrophils includes the release of hepatocyte growth factor, vascular endothelial growth factor A, matrix metalloproteinase-9, and angiopoietin 1. The increase in these same proteins 24 hours after G-CSF administration in the CLTI population treated above may thus be attributable to neutrophilia. Moreover, neutrophils secrete proteases that degrade thrombus and have context-dependent fibrinolytic capacity. Conclusions Induced neutrophilia can promote a proangiogenic and profibrinolytic environment in the specific context of chronically ischemic tissue. This article was prepared to facilitate further research into this potential transformative medical treatment for CLTI, with benefit potential in other chronically ischemic beds.
No takes yet. Share an insight, caveat, or question.
Darwin Eton (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: